303-16-2

Basic information

• Product Name: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione;3151IS;3-Phthalimidylpyrrolidine-2,5-dione;EM-20;N-(2,5-Dioxo-3-pyrrolidinyl)phthalimide;1H-Isoindole-1,3(2H)-dione, 2-(2,5-dioxo-3-pyrrolidinyl)- (9ci);2-Ftalimmidosuccinimide;2-Ftalimmidosuccinimide [italian]
• CAS NO: 303-16-2
• Molecular Formula: C₁₂H₈N₂O₄
• Molecular Weight: 244.2029
• Mol File: 303-16-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 500.9°Cat760mmHg
• Flash Point: 256.7°C
• Appearance: /
• Density: 1.585g/cm³
• Vapor Pressure: 3.65E-10mmHg at 25°C
• Refractive Index: 1.673
• CAS DataBase Reference: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(303-16-2)
• EPA Substance Registry System: 2-(2,5-Dioxopyrrolidine-3-yl)-1H-isoindole-1,3(2H)-dione(303-16-2)

Safety Data

• Hazardous Substances Data: 303-16-2(Hazardous Substances Data)

Usage

Molecular structure

Heterocyclic compound with a complex structure, containing both pyrrolidine and isoindole rings.

Molecular weight

267.24 g/mol

Functional groups

Contains pyrrolidine, isoindole, and dione functional groups.

Potential applications

May have use in pharmaceuticals, organic synthesis, and material science.

Research status

Further research and study needed to fully understand its properties and potential uses.

InChI:InChI=1/C12H8N2O4/c15-9-5-8(10(16)13-9)14-11(17)6-3-1-2-4-7(6)12(14)18/h1-4,8H,5H2,(H,13,15,16)

Upstream product

• 85-44-9 phthalic anhydride 
• 5615-80-5 L-3-aminosuccinimide 

Relevant articles and documents

NEW CRBN MODULATORS

Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.

TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS

The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

Studies of unusual amino acids and their peptides. V. The synthesis and the absolute configuration of β (2 thiazolyl) β alanine present in bottromycin

-